Diagnosis and treatment of anti-myelin oligodendrocyte glycoprotein antibody positive optic neuritis
- 594 Downloads
Anti-myelin-oligodendrocyte glycoprotein (MOG) antibody positive optic neuritis has been established as a new subset of optic neuropathy. Anti-MOG antibodies are usually measured by cell-based assay. Patients with anti-MOG antibody positive optic neuritis respond well to steroid therapy, and, while visual acuity outcomes are favorable, significant visual field defects remain. Furthermore, patients who are anti-MOG antibody positive have higher rates of recurrence compared to antibody negative patients. Based on these findings, anti-MOG antibody positive patients with optic neuritis have the characteristics of good visual outcomes, residual visual field defects, and high risk of recurrence. Tests for anti-MOG antibody are useful for the diagnosis and treatment of optic neuritis.
KeywordsAnti-myelin oligodendrocyte glycoprotein antibody Anti-MOG antibody Optic neuritis Chronic recurrent inflammatory optic neuropathy
We thank Ms. Teresa Nakatani for critical revision of the manuscript. This work was supported in part by Health and Labor Sciences Research Grants for research on intractable diseases from the Ministry of Health, Labour, and Welfare of Japan.
Conflicts of interest
T. Kezuka, None; H. Ishikawa, None.
- 11.Baumann M, Sahin K, Lechner C, Hennes EM, Schanda K, Mader S, et al. Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatr. 2015;86(265–72):7.Google Scholar
- 17.Goseki T. Refractory optic neuritis nation survey in Japan. Rinsho Ganka (in Japanese). 2017;71:1688–90.Google Scholar
- 22.Pache F, Zimmermann H, Mikolajczak J, Schumacher S, Lacheta A, Oertel FC, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. J Neuroinflamm. 2016;13:282.CrossRefGoogle Scholar
- 27.Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K. In cooperation with the Neuromyelitis Optica Study Group (NEMOS). MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflamm. 2016;13:280.CrossRefGoogle Scholar
- 28.Martinez-Lapiscina EH, Sepulveda M, Torres-Torres R, Alba-Arbalat S, Llufriu S, Blanco Y, et al. Usefulness of optical coherence tomography to distinguish optic neuritis associated with AQP4 or MOG in neuromyelitis optica spectrum disorders. Ther Adv Neurol Disord. 2016;9:436–40.CrossRefPubMedPubMedCentralGoogle Scholar
- 32.Wakakura M, Minei-Higa R, Oono S, Matsui Y, Tabuchi A, Kani K, et al. Baseline features of idiopathic optic neuritis as determined by a multicenter treatment trial in Japan. Optic Neuritis Treatment Trial Multicenter Cooperative Research Group (ONMRG). Jpn J Ophthalmol. 1999;43:127–32.CrossRefPubMedGoogle Scholar